Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults

Journal of Acquired Immune Deficiency Syndromes

Volumn 67, Issue 5, 2014, Pages 487-492

  Spreen, William ^a   Williams, Peter ^b   Margolis, David ^a   Ford, Susan L ^a   Crauwels, Herta ^b   Lou, Yu ^a   Gould, Elizabeth ^a   Stevens, Marita ^b   Piscitelli, Stephen ^a  

^a GLAXOSMITHKLINE   (United States)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

GSK1265744; Injections; Long acting; Nanosuspension; Pharmacokinetics; Rilpivirine; TMC278

Indexed keywords

CABOTEGRAVIR; RILPIVIRINE; DELAYED RELEASE FORMULATION; NITRILE; PYRIDONE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; APPENDICITIS; AREA UNDER THE CURVE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ECG ABNORMALITY; FEMALE; HUMAN; HUMAN EXPERIMENT; INJECTION SITE REACTION; LONG TERM EXPOSURE; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NORMAL HUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TIME TO MAXIMUM PLASMA CONCENTRATION; ADOLESCENT; ADULT; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DRUG COMBINATION; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION; YOUNG ADULT;

ADOLESCENT; ADULT; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; NITRILES; PYRIDONES; PYRIMIDINES; YOUNG ADULT;

EID: 84921020451     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000365     Document Type: Conference Paper

References (9)

1. Arribas JR, Eron J. Advances in antiretroviral therapy. Curr Opin HIV AIDS. 2013;8:341-349.
2. Llibre JM, Clotet B. Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment. AIDS Rev. 2012;14:168-178.
3. Ammassari A, Trotta MP, Shalev N, et al. Beyond virological suppression: the role of adherence in the late HAART era. Antivir Ther. 2012;17:785-792.
4. Spreen W, Min S, Ford SL, et al. Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor. HIV Clin Trials. 2013;14:192-203.
5. Spreen W, Ford SL, Chen S, et al. GSK1265744 pharmacokinetics in plasma and tissue following single-dose long-acting injectable administration in healthy subjects. J Acquir Immune Defic Syndr. 2014; [Epub ahead of print; August 21, 2014].
6. van 't Klooster G, Hoeben E, Borghys H, et al. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob Agents Chemother. 2010;54:2042-2050.
7. Crauwels HM, Van Heeswijk RP, Buelens A, et al. Impact of food and different meal types on the pharmacokinetics of rilpivirine. J Clin Pharmacol. 2013;53:834-840.
8. Margolis D, Brinson C, Eron J, et al. 744 and rilpivirine as two drug oral maintenance therapy: LAI116482 (LATTE) week 48 results. Abstract presented at: 21st Conference on Retroviruses and Opportunistic Infections;March 3-6, 2014; Boston, MA. Abstract 91LB.
9. Crauwels H, van Schaick E, van Heeswijk R, et al. Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral-naive, HIV-1-infected patients in ECHO and THRIVE. Abstract presented at: 10th International Congress on Drug Therapy in HIV Infection; November 7-11, 2010; Glasgow, United Kingdom. Abstract P186.